icad inc. (NASDAQ:ICAD) posted its earnings results on Wednesday. The technology company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01, Bloomberg Earnings reports. The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.43 million. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%.

icad inc. (NASDAQ ICAD) traded down $0.44 during trading on Thursday, hitting $3.62. The company’s stock had a trading volume of 134,262 shares, compared to its average volume of 42,414. icad inc. has a twelve month low of $3.10 and a twelve month high of $6.07.

A number of research firms have commented on ICAD. ValuEngine raised icad inc. from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Laidlaw reissued a “buy” rating and issued a $11.00 target price on shares of icad inc. in a report on Tuesday, July 25th.

ILLEGAL ACTIVITY NOTICE: “icad inc. (ICAD) Issues Earnings Results” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/09/icad-inc-icad-issues-earnings-results.html.

In other icad inc. news, Director Dr Lawrence Howard bought 10,000 shares of icad inc. stock in a transaction on Wednesday, August 23rd. The stock was acquired at an average price of $3.33 per share, with a total value of $33,300.00. Following the acquisition, the director now owns 488,022 shares in the company, valued at $1,625,113.26. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 19.20% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in icad inc. stock. Vanguard Group Inc. increased its position in icad inc. (NASDAQ:ICAD) by 0.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 456,377 shares of the technology company’s stock after acquiring an additional 2,007 shares during the period. Vanguard Group Inc. owned about 2.79% of icad inc. worth $1,912,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 23.14% of the company’s stock.

icad inc. Company Profile

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

Earnings History for icad inc. (NASDAQ:ICAD)

Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.